MACROGENICS, INC. Payments to Acquire Debt Securities, Available-for-sale
MACROGENICS, INC. (MGNX) reported Payments to Acquire Debt Securities, Available-for-sale of $35.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-14
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $33.13M, a 27.21% decline year-over-year.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $1.98M, a 74.98% decline year-over-year.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $88.85M, a 544.37% increase year-over-year.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $66.06M, a 1251.24% increase year-over-year.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $208.34M, a 169.93% increase from fiscal 2024.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $77.18M, a 67.80% decline from fiscal 2023.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $239.68M, a 98.74% increase from fiscal 2022.
- MACROGENICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $120.60M, a 47.84% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $33.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $35.11M 10-Q · filed 2026-08-14 | $123.95M derived: sum of 3 quarters · filed 2026-08-14 | $190.02M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-13 | $90.83M derived: sum of 2 quarters · filed 2026-05-13 | $156.89M derived: sum of 3 quarters · filed 2026-05-13 | $202.40M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $88.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $154.91M derived: sum of 2 quarters · filed 2026-03-09 | $200.42M derived: sum of 3 quarters · filed 2026-08-14 | $208.34M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $66.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $111.58M derived: sum of 2 quarters · filed 2026-08-14 | $119.49M 10-Q · filed 2025-11-12 | $133.28M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $45.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $53.43M 10-Q · filed 2026-08-14 | $67.22M derived: sum of 3 quarters · filed 2026-08-14 | $72.11M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $7.92M 10-Q · filed 2026-05-13 | $21.70M derived: sum of 2 quarters · filed 2026-05-13 | $26.59M derived: sum of 3 quarters · filed 2026-05-13 | $34.60M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $13.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $18.68M derived: sum of 2 quarters · filed 2026-03-09 | $26.68M derived: sum of 3 quarters · filed 2026-03-09 | $77.18M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $4.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $12.90M derived: sum of 2 quarters · filed 2025-11-12 | $63.39M 10-Q · filed 2025-11-12 | $85.86M derived: sum of 4 quarters · filed 2026-03-09 | |
| 2024-06-30 | $8.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $58.51M 10-Q · filed 2025-08-14 | $80.97M derived: sum of 3 quarters · filed 2026-03-09 | $150.15M derived: sum of 4 quarters · filed 2026-03-09 | |
| 2024-03-31 | $50.50M 10-Q · filed 2025-05-13 | $72.96M derived: sum of 2 quarters · filed 2026-03-09 | $142.14M derived: sum of 3 quarters · filed 2026-03-09 | $272.88M derived: sum of 4 quarters · filed 2026-03-09 | |
| 2023-12-31 | $22.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $91.64M derived: sum of 2 quarters · filed 2026-03-09 | $222.39M derived: sum of 3 quarters · filed 2026-03-09 | $239.68M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $69.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $199.92M derived: sum of 2 quarters · filed 2024-11-05 | $217.22M 10-Q · filed 2024-11-05 | $262.36M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2023-06-30 | $130.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $148.04M 10-Q · filed 2024-08-06 | $193.19M derived: sum of 3 quarters · filed 2025-03-20 | $193.19M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2023-03-31 | $17.30M 10-Q · filed 2024-05-09 | $62.44M derived: sum of 2 quarters · filed 2025-03-20 | $62.44M derived: sum of 3 quarters · filed 2025-03-20 | $83.82M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2022-12-31 | $45.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $45.15M derived: sum of 2 quarters · filed 2025-03-20 | $66.53M derived: sum of 3 quarters · filed 2025-03-20 | $120.60M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $21.38M derived: sum of 2 quarters · filed 2023-11-06 | $75.46M 10-Q · filed 2023-11-06 | $141.88M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2022-06-30 | $21.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $75.46M 10-Q · filed 2023-08-09 | $141.88M derived: sum of 3 quarters · filed 2024-03-07 | $189.12M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2022-03-31 | $54.08M 10-Q · filed 2023-05-09 | $120.50M derived: sum of 2 quarters · filed 2024-03-07 | $167.74M derived: sum of 3 quarters · filed 2024-03-07 | $191.40M derived: sum of 4 quarters · filed 2024-03-07 | |
| 2021-12-31 | $66.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $113.66M derived: sum of 2 quarters · filed 2024-03-07 | $137.33M derived: sum of 3 quarters · filed 2024-03-07 | $231.21M 10-K · filed 2024-03-07 | |
| 2021-09-30 | $47.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $70.90M derived: sum of 2 quarters · filed 2022-11-03 | $164.78M 10-Q · filed 2022-11-03 | $237.29M derived: sum of 4 quarters · filed 2023-03-15 | |
| 2021-06-30 | $23.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $117.55M 10-Q · filed 2022-08-08 | $190.06M derived: sum of 3 quarters · filed 2023-03-15 | $269.09M derived: sum of 4 quarters · filed 2023-03-15 | |
| 2021-03-31 | $93.88M 10-Q · filed 2022-05-03 | $166.40M derived: sum of 2 quarters · filed 2023-03-15 | $245.43M derived: sum of 3 quarters · filed 2023-03-15 | $256.44M derived: sum of 4 quarters · filed 2023-03-15 | |
| 2020-12-31 | $72.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $151.55M derived: sum of 2 quarters · filed 2023-03-15 | $162.56M derived: sum of 3 quarters · filed 2023-03-15 | $223.75M 10-K · filed 2023-03-15 | |
| 2020-09-30 | $79.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $90.04M derived: sum of 2 quarters · filed 2021-11-02 | $151.23M 10-Q · filed 2021-11-02 | $201.45M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $11.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $72.20M 10-Q · filed 2021-07-29 | $122.42M derived: sum of 3 quarters · filed 2022-02-24 | $194.29M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $61.19M 10-Q · filed 2021-04-29 | $111.41M derived: sum of 2 quarters · filed 2022-02-24 | $183.28M derived: sum of 3 quarters · filed 2022-02-24 | $243.99M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $50.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $122.09M derived: sum of 2 quarters · filed 2022-02-24 | $182.80M derived: sum of 3 quarters · filed 2022-02-24 | $264.40M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $71.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $132.58M derived: sum of 2 quarters · filed 2020-11-04 | $214.18M 10-Q · filed 2020-11-04 | $226.89M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $60.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $142.31M 10-Q · filed 2020-07-31 | $155.02M derived: sum of 3 quarters · filed 2021-02-25 | $188.56M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $81.60M 10-Q · filed 2020-05-05 | $94.31M derived: sum of 2 quarters · filed 2021-02-25 | $127.86M derived: sum of 3 quarters · filed 2021-02-25 | $189.90M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $46.26M derived: sum of 2 quarters · filed 2021-02-25 | $108.30M derived: sum of 3 quarters · filed 2021-02-25 | $132.75M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $33.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $95.59M derived: sum of 2 quarters · filed 2019-11-06 | $120.04M 10-Q · filed 2019-11-06 | $166.04M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $62.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $86.49M 10-Q · filed 2019-07-31 | $132.49M derived: sum of 3 quarters · filed 2020-02-25 | $164.68M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $24.45M 10-Q · filed 2019-05-01 | $70.45M derived: sum of 2 quarters · filed 2020-02-25 | $102.64M derived: sum of 3 quarters · filed 2020-02-25 | $102.64M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2017-12-31 | $46.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $78.19M derived: sum of 2 quarters · filed 2020-02-25 | $78.19M derived: sum of 3 quarters · filed 2020-02-25 | $135.12M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $32.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $32.19M derived: sum of 2 quarters · filed 2018-11-07 | $89.12M 10-Q · filed 2018-11-07 | $167.19M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $56.94M 10-Q · filed 2018-08-07 | $135.00M derived: sum of 3 quarters · filed 2019-02-26 | $202.31M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $56.94M 10-Q · filed 2018-05-07 | $135.00M derived: sum of 2 quarters · filed 2019-02-26 | $202.31M derived: sum of 3 quarters · filed 2019-02-26 | $321.58M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $78.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $145.37M derived: sum of 2 quarters · filed 2019-02-26 | $264.65M derived: sum of 3 quarters · filed 2019-02-26 | $347.76M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $67.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $186.58M derived: sum of 2 quarters · filed 2017-11-08 | $269.70M 10-Q · filed 2017-11-08 | $412.61M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $119.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $202.39M 10-Q · filed 2017-08-02 | $345.30M derived: sum of 3 quarters · filed 2018-02-27 | $345.30M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $83.12M 10-Q · filed 2017-05-03 | $226.03M derived: sum of 2 quarters · filed 2018-02-27 | $226.03M derived: sum of 3 quarters · filed 2018-02-27 | $226.03M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $142.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $142.91M derived: sum of 2 quarters · filed 2018-02-27 | $142.91M derived: sum of 3 quarters · filed 2018-02-27 | $142.91M 10-K · filed 2018-02-27 | -$142.91M 10-K · filed 2016-02-29 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $0.00 derived: sum of 2 quarters · filed 2016-11-02 | $0.00 10-Q · filed 2016-11-02 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $0.00 10-Q · filed 2016-08-03 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-04 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |